Skip to main content
Premium Trial:

Request an Annual Quote

SIRS-Lab, Pfizer Target Sepsis with MDx Tests

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Molecular diagnostics firm SIRS-Lab today announced a collaboration with Pfizer Pharma focused on sepsis diagnostics and treatment.

The firms will initially evaluate the clinical impact of using molecular-based tests for diagnosis of severe fungal blood stream infections, as well as the pharmacoeconomics of such an approach.

Financial and other terms of the deal were not disclosed.

Each year, more than 2 million people in Europe and North America are affected by sepsis, a leading cause of death in hospitals. In a statement, SIRS-Lab said that patients with sepsis may not be receiving proper treatment, as evidence of antibiotic resistance mounts. With molecular diagnostic tests, a microbe can be identified in a few hours, leading to quicker tailoring of the treatment.

Based in Jena, Germany, SIRS-Lab develops and commercializes products for the diagnosis and monitoring of life-threatening infections. It has developed a proprietary sample preparation technology called Looxster, used within the company's Vyoo CE-marked sepsis test. Another test being planned for launch, Siqnature, monitors the body's immune response to infection through gene expression.

The Scan

New Study Highlights Role of Genetics in ADHD

Researchers report in Nature Genetics on differences in genetic architecture between ADHD affecting children versus ADHD that persists into adulthood or is diagnosed in adults.

Study Highlights Pitfall of Large Gene Panels in Clinical Genomic Analysis

An analysis in Genetics in Medicine finds that as gene panels get larger, there is an increased chance of uncovering benign candidate variants.

Single-Cell Atlas of Drosophila Embryogenesis

A new paper in Science presents a single-cell atlas of fruit fly embryonic development over time.

Phage Cocktail Holds Promise for IBD

Researchers uncovered a combination phage therapy that targets Klebsiella pneumonia strains among individuals experiencing inflammatory bowel disease flare ups, as they report in Cell.